Case 1: A 54-year-old man with
|
|
- Mitchell Parrish
- 5 years ago
- Views:
Transcription
1 CLINICIAN UPDATE -Blockers in Chronic Heart Failure Mihai Gheorghiade, MD; Wilson S. Colucci, MD; Karl Swedberg, MD Case 1: A 54-year-old man with a history of myocardial infarction (MI) presented with exertional dyspnea. Physical examination was unremarkable. Left ventricular ejection fraction (LVEF) by Doppler echocardiography was 35%, and a stress test was negative for ischemia. The patient was taking aspirin, a statin, and an angiotensin converting enzyme (ACE) inhibitor. He was started on 12.5 mg/d metoprolol controlled-release/extended release (CR/XL) and titrated to a target dose of 200 mg/d over several weeks. Case 2: A 65-year-old woman with a history of heart failure (HF) due to hypertension (HTN) continued to have dyspnea with exertion and occasionally at rest. On physical examination, there was no jugular venous distention or ankle edema. Her LVEF was 10%. She was taking a loop diuretic, digoxin, and an ACE inhibitor; mg twice/d carvedilol was added and slowly titrated to a target dose of 25 mg twice/d. Chronic HF is a common clinical syndrome resulting from coronary artery disease (CAD), HTN, valvular heart disease, and/or primary cardiomyopathy. 1,2 There is now conclusive evidence that -blockers, when added to ACE inhibitors, substantially reduce mortality, decrease sudden death, and improve symptoms in patients with HF. Despite the overwhelming evidence 3 6 and guidelines 1,7,8 that mandate the use of -blockers in all HF patients without contraindications, many patients do not receive this treatment. 9 Demographics of HF In the United States, approximately 70% of patients with HF have CAD. 10,11 Hypertension is a major risk factor for HF, 11 particularly in blacks. An increasing number of HF patients have diabetes. Although the term congestive HF continues to be used, most patients, even those with severe symptoms, may have few or no signs of congestion. 9 Often, if signs of congestion are not present, HF is not diagnosed, and these patients are therefore not considered for treatment. Approximately 40% of patients with HF have preserved systolic function, 12 frequently associated with HTN, CAD, diabetes, and/or atrial fibrillation. Such patients have diastolic dysfunction that is age related (for more information, see the Clinician Update by Grossman and Angeja 13 ). Sudden death accounts for the majority of deaths in HF patients, is more common (versus progressive circulatory failure) in patients with milder symptoms, 5 and can occur before the development of symptoms or after symptoms have been well controlled. Because of its diverse pathophysiology and presentations, there is no uniform classification for all the clinical manifestations of HF. However, the American College of Cardiology/ American Heart Association 1 recently released guidelines that described the 4 stages of HF (Table 1). Mechanism of Beneficial -Blocker Effects in HF After a myocardial insult acute (eg, MI) or chronic (eg, HTN) that results in LV dysfunction, there is an increased activity of the renin-angiotensin and sympathetic nervous systems. 1 Sympathetic nervous system activation may accelerate LV remodeling, worsen myocardial function, and lower the threshold for life-threatening arrhythmias. 1 Progression of CAD also may contribute to worsening of HF. 10 It is possible that by reducing the harmful effects of excessive and continous increased adrenergic drive on the myocardium, -blockers cause time-dependent improvements in ventricular structure and function. Other likely beneficial actions include reductions in heart rate and blood pressure, From the Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill (M.G.); Cardiovascular Section, Boston University Medical Center, Boston, Mass (W.S.C.); and the Department of Medicine, Sahlgrenska University Hospital/Ostra, Göteborg, Sweden (K.S.). Correspondence to Mihai Gheorghiade, MD, Northwestern University, Feinberg School of Medicine, 201 East Huron St, Galter , Chicago, IL m-gheorghiade@northwestern.edu (Circulation. 2003;107: ) 2003 American Heart Association, Inc. Circulation is available at DOI: /01.CIR
2 Gheorghiade et al -Blockers in Chronic Heart Failure 1571 TABLE 1. Heart Failure Stages, Indications, Contraindications, and Relative Contraindications to -Blockers Stage Description 1 A Patients at high-risk of developing HF. These are patients with CAD, diabetes, HTN, and/or valvular heart disease. B C D inhibition of the renin-angiotensin system, reduction of atrial and ventricular arrhythmias, and anti-ischemic effects. -Blockers improve the contractility of viable but not contractile myocardial regions in patients with ischemic (hibernating myocardium) and nonischemic etiology. 14 The beneficial effects of chronic -blockade in HF occur despite an initial and transient decrease in contractility. 15 TABLE 2. Structural heart disease but without clinical HF symptoms, many of whom have decreased systolic function. Patients who have prior or current symptomatic HF due to systolic or diastolic dysfunction and who are responding to therapy. Patients with end-stage or refractory-to-therapy HF. No. of Patients (United States Estimate) Indications Contraindications Relative Contraindications 50 million 8 to 10 million 5 million In addition to ACE inhibitors, -blockers should be considered in patients with CAD, particularly if they are post-mi and/or have angina, and in patients with hypertension. 1 Should be prescribed to all patients with systolic dysfunction, regardless of its etiology. 1 Should be used in all patients with systolic dysfunction in addition to diuretics, ACE inhibitors, and, depending on symptoms, digoxin and low-dose spironolactone. 1 Patients with HF and preserved systolic function should also receive a -blocker if they have hypertension, CAD, or atrial fibrillation. In selected patients who are not dependent on intravenous inotropes or intravenous diuretics. 1 Evidence Supporting the Use of -Blockers in HF Background The initial experience with -blockers in HF was reported in 1975, 16 and the first observations on survival were made in However, the first multicenter randomized trial was not published until 1993, 18 and it was 1997 before a -blocker (carvedilol) was first approved for the treatment of HF. Major Placebo-Controlled Trials of -Blockade in Heart Failure Target Dosage, mg -blockers are contraindicated in patients with: advanced heart block asthma or reactive airways disease that is not related to HF and requires bronchodilator therapy a heart rate 50 bpm (unless a pacemaker is present) systolic blood pressure 85 mm Hg. 1 Mean Dosage Achieved, mg/d The reason for the slow acceptance of -blocker therapy for HF seems to be related to the transient negative inotropic effect of acute -blockade and the attendant risk of decompensation in patients with HF. Randomized Clinical Trials The available randomized data overwhelming show that carvedilol, metoprolol CR/XL, and bisoprolol reduce Effect on All-Cause Mortality -blockers can be used with caution in HF patients with COPD, diabetes, and peripheral vascular disease. The available data suggest that these patients are at particularly high risk for major cardiovascular events and derive a significant benefit from -blocker therapy. -blockers can also be used with caution in patients with HF associated with asymptomatic hypotension, sinus bradycardia (50 to 60 bpm), depression, and cocaine abuse. Effect on All-Cause Hospitalization Study Drug HF Severity Patients, n Follow-up, mean years US Carvedilol 3 Carvedilol Mild/Moderate months 6.25 to 50 bid % (P 0.001) 2 27% (P 0.036) CIBIS-II 4 Bisoprolol* Moderate/Severe qd % (P ) 2 20% (P ) MERIT-HF 5 Metoprolol CR/XL Mild/Moderate qd % (P ) 2 18% (P 0.004) BEST 31 Bucindolol* Moderate/Severe to 100 bid 152 NS 2 8% (P 0.08) COPERNICUS 6 Carvedilol Severe months 25 bid % (P ) 2 20% (P 0.002) CIBIS-II indicates Cardiac Insufficiency BIsoprolol Study II; MERIT-HF, MEtoprolol CR/XL Randomized Intervention Trial in congestive heart failure; BEST, Beta-Blocker Evaluation of Survival Trial; COPERNICUS, CarvedilOl ProspEctive RaNdomIzed CUmulative Survival trial; and NS, not significant. *Not FDA approved in United States. Mortality not a planned end point.
3 1572 Circulation April 1, 2003 morbidity and mortality in minimally, moderately, or severely symptomatic patients with HF (Table 2). It is noteworthy that -blockers were used in addition to ACE inhibitors in all of these trials. Even so, the incremental mortality benefits observed with these -blockers are greater than those observed with ACE inhibitors alone or with other classes of agents. Practical Aspects of Using -Blockers for HF Treatment Indications/Contraindications to -Blocker Therapy/Relative Contraindications Table 1 describes the stages of HF, indications for therapy, contraindications, and relative contraindications. Starting Dose and Titration Carvedilol, metoprolol CR/XL, and bisoprolol have been shown to reduce mortality and morbidity in HF. However, only carvedilol and metoprolol CR/XL are approved for HF in the United States, whereas bisoprolol is approved in several European countries. The Figure describes the initiation, titration steps, and target doses. Target doses should be achieved and are strongly recommended. 1 A study showing clinical benefit of carvedilol at lower doses 19 and retrospective subgroup analyses with metoprolol CR/ XL 20 suggest that if a higher (target) dose is not tolerated, then the highest tolerated dose should be maintained. Which -Blocker? Studies have shown that carvedilol, metoprolol CR/XL, and bisoprolol are efficacious in patients with moderate and mild-to-moderate HF. Carvedilol was also shown to benefit post-mi patients with LV systolic dysfunction 21 and patients in New York Heart Association functional class IV (symptoms at rest) without signs of congestion. 6 These agents are recommended for the treatment of HF. Other -blockers, such as atenolol or propranolol, have not been adequately tested in HF and should not be considered as primary therapy. -Blocker treatment algorithm for chronic heart failure (ACC/AHA stages C and D in patients with reduced systolic function). ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BUN/Cr, Blood urea nitrogen/creatinine; HR, heart rate; IV, intravenous; NSAIDs, nonsteroidal anti-inflammatory drugs; and SBP, systolic blood pressure. *Most patients with HF and preserved systolic function will benefit from -blockade therapy (eg, those with coronary artery disease, atrial fibrillation, and hypertension). Not FDA approved in United States. Although -blockers share a common class effect in that they all block the 1 -adrenergic receptor, they can also differ markedly in their pharmacological profiles. Metoprolol CR/XL and bisoprolol are selective for the 1 -receptor. Carvedilol blocks both the 1 - and 2 -receptors and the 1 - adrenergic receptor, thereby resulting in peripheral vasodilation. Carvedilol increases insulin sensitivity, whereas metoprolol does not. 22 A potentially beneficial direct antioxidant effect of carvedilol was shown, 22 although there is evidence that -blockade per se reduces oxidative stress in patients with HF. 23 -Blockers may differ with regard to intrinsic sympathomimetic
4 Gheorghiade et al -Blockers in Chronic Heart Failure 1573 activity and lipophilicity. Because it is not yet clear whether these or other pharmacological distinctions translate into meaningful clinical differences, it cannot be assumed that all -blockers will exert similar beneficial effects in HF. The CarvedilOl and Metoprolol European Trial (COMET), 24 which compares the effects of metoprolol tartrate and carvedilol in 3000 patients, should yield relevant data later this year. Using -Blockers in Combination With Other HF Therapies -Blockers should be used in patients already receiving an ACE inhibitor; however, it is likely that they also benefit patients not taking an ACE inhibitor. 25 If there are signs and symptoms of HF, diuretics, digoxin, and low-dose spironolactone should be included when appropriate. 1,3,4,26 Patients need not take target doses of ACE inhibitors before initiating therapy with -blockers. However, the doses of both ACE inhibitors and -blockers should ultimately be maximized. 26 Because their use may predispose the patient to sodium accumulation, -blocker should not be initiated if patients are fluid-overloaded. They should always be prescribed with a diuretic in patients that are likely to develop fluid retention. 26 The triple combination of an ACE inhibitor, -blocker, and angiotensin receptor blocker may increase mortality and should be avoided. 1,27 Using -Blockers in HF Patients With Comorbidities After MI: Use in all patients without a contraindication. Carvedilol reduced all-cause mortality or nonfatal reinfarction by approximately 30% when used in combination with ACE inhibitors and aspirin in patients with systolic dysfunction, with or without symptoms. 21 Chronic obstructive pulmonary disease: Chronic obstructive pulmonary disease not associated with severe reactive airways disease is not a contraindication to -blockers. 26,28 Peripheral vascular disease: Using lower than target doses, 1 - selectivity (eg, metoprolol CR/XL or bisoprolol) or concomitant 1 - blockade (eg, carvedilol) may increase tolerability in patients with symptomatic claudication. Diabetes mellitus: Diabetic patients with HF have a worse prognosis than non-diabetics with HF. 29 Although in general, -blockade exerts adverse effects on the metabolic profile in diabetic patients, subgroup analyses from bisoprolol, 4 metoprolol CR/XL, 5 and carvedilol trials suggest that diabetic patients with HF derive significant morbidity and mortality benefits with these agents. Because of its 1 -blocking effects, carvedilol may have neutral effects with respect to lipid profile and insulin sensitivity. 22,30 Using -Blockers in Specific Populations Age: Subgroup analyses of the major -blocker HF trials have shown a similar benefit in patients 65 years old as seen in the general population. 3,5,6,31 Thus, age should not be a deterrent to the use of -blockers in elderly patients with HF. Gender: Women represented 20% to 30% of the population in the -blocker HF trials (Table 2) 3,5 6 and appear to benefit from -blocker therapy. Ethnicity: There is little information regarding possible ethnic differences in the response to -blockers in HF. However, in one study, carvedilol substantially reduced the risk of death in blacks. 3,32 Diastolic HF: Although it is estimated that 40% of HF patients have preserved systolic function, there are no randomized data regarding the effects of -blockers on outcomes. 1 However, the majority of these patients often have HTN, CAD, and/or atrial fibrillation, conditions for which -blockers are indicated. Clinical Management Issues Volume Overload Incidence of adverse effects are listed in Table 3. -blockers should not be initiated in patients with moderate to severe fluid retention. HF is a progressive disease, and it is likely that during its course, many patients will develop signs and symptoms related to fluid retention. The initial approach to such patients should be to intensify fluid management, most often by increasing the dose or adding a second diuretic. Uptitration of a -blocker should be delayed when volume overload is present. Daily weighing is important, as weight gain often precedes the development of symptoms by several days. If there is a gain in weight (2 to 3 lbs/d or 4 to 5 lbs over a few days), the diuretic dose should be increased even before symptoms develop. Hypotension Asymptomatic hypotension is common in patients with severe HF, and in itself it is not a contraindication to -blocker therapy. 6 It is important to determine by obtaining supine and standing blood pressures that the hypotension is not caused by an inadequate preload related to aggressive use of diuretics or ACE inhibitors. In some cases, it may be necessary to adjust the dose and/or timing of concomitant therapy with ACE inhibitors, other vasodilators, and/or diuretic. Bradycardia -Blockers can be used in patients who have asymptomatic and mild bradycardia, particularly when the heart rate increases with exercise. The possibility of drug interactions that may lower heart rate (eg, digoxin and amiodarone) should also be considered. Given the substantial benefits of -blockers in HF, cardiac pacing should be considered on an individual basis. 1 Asymptomatic bradycardia during -blocker therapy is not a reason for its discontinuation. -Blocker Discontinuation Abrupt discontinuation of -blocker therapy in HF should be avoided be-
5 1574 Circulation April 1, 2003 TABLE 3. Incidence of Adverse Events With -Blockade in Heart Failure Trials Depression, % Fatigue, % Sexual Dysfunction, % Dizziness, % Bradycardia, % Worsening Heart Failure, % Trial (Drug) Active Placebo Active Placebo Active Placebo Active Placebo Active Placebo Active Placebo US Carvedilol 3 (Carvedilol) * 22.4* 32.4* 19.2* 8.8* 0.9* CIBIS-II 4 (Bisoprolol) 0* 0.8* 6.6* 1.5* NA NA 2.9* 3.8* 0.4* 0* MERIT-HF 5 (Metoprolol CR/XL) 0.05* NA NA NA 1.8* 1.0* 1.5* 0.4* BEST 31 (Bucindolol) NA NA COPERNICUS 6 (Carvedilol) NA NA NA NA NA NA NA indicates not available. See Table 2 for study abbreviations. *Prescribing information. Incidences 1% to 2% were reported more frequently with carvedilol in US placebo-controlled trial (prescribing information). Lead to discontinuation of the study drug. Lead to withdrawal of study drug. Hospital admission for worsening heart failure. cause it may be associated with rebound effects and increased morbidity and mortality, even in patients without overt HF. In patients presenting with worsening HF while taking -blockers, the first consideration should be to achieve compensation by adjusting other medications, including diuretics, digoxin, and ACE inhibitors, before decreasing the dose of or discontinuing the -blocker. Most patients admitted for HF have congestion without signs of hypoperfusion and will respond to standard HF therapy. 33 An important exception is the patient presenting with hypotension and signs of organ hypoperfusion. In such patients, -blockers should be decreased or discontinued and supportive therapy with a phosphodiesterase inhibitor (eg, milrinone) may be considered. Initiating -Blocker Therapy in the Hospital One approach to increasing the overall implementation of -blocker therapy is the initiation of therapy before discharge from the hospital. Preliminary evidence suggests that, with proper caution and patient selection, this can be accomplished safely. 34 Conclusion More than 5 years after the first approval of a -blocker for the treatment of HF by the Food and Drug Administration, this life-saving therapy continues to be underutilized. Given the recommendation to use -blockade in all HF patients without a contraindication, more effort is needed to improve the dissemination of the scientific, clinical, and practical aspects of -blocker therapy for HF to physicians, healthcare providers, and patients. References 1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38: American Heart Association Heart and Stroke Statistical Update. Available at: Accessed February 28, Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334: The CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353: The MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353: Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe 344: Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approaches. J Card Fail. 1999;5: Remme WJ, Swedberg K. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail. 2002;4: Gheorghiade M, Bonow RO. Introduction and overview: beta-blocker therapy in the management of chronic heart failure. Am J Med. 2001;110(suppl 7A):1S 5S. 10. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97: Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106: McDermott MM, Feinglass J, Lee P, et al. Heart failure between 1986 and 1994: temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center. Am Heart J. 1997;134: Grossman W, Angeja B. Evaluation and management of diastolic heart failure. Circulation. 2003;107: Ramahi TM, Longo MD, Cadariu AR, et al. Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after betablocker therapy in nonischemic cardiomyopathy. J Am Coll Cardiol. 2001;37: Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25: Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37: Swedberg K, Hjalmarson A, Waagstein F, et al. Prolongation of survival in congestive
6 Gheorghiade et al -Blockers in Chronic Heart Failure 1575 cardiomyopathy by beta-receptor blockade. Lancet. 1979;1: Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342: Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94: Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol. 2002;40: The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357: Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14: Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999;99: Poole-Wilson PA, Cleland JG, Di Lenarda A, et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur J Heart Fail. 2002;4: Remme WJ. Carvedilol ACE inhibitor remodeling mild CHF evaluation trial: new data demonstrate carvedilol reverses heart damage. Presented at the 2002 European Society of Cardiology Congress, September 3, 2002; Berlin, Germany. 26. Gheorghiade M, Eichhorn EJ. Practical aspects of using beta-adrenergic blockade in systolic heart failure. Am J Med. 2001; 110(suppl 7A):68S 73S. 27. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in 345: Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339: Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77: Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulindependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med. 1997;126: The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the betablocker bucindolol in patients with advanced 344: Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with 344: Gattis WA, O Connor CM, Leimberger JD, et al. Clinical outcomes in patients on betablocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003;91: Gattis W, O Connor CM, Gheorghiade M. The initiation management predischarge process for assessment of carvedilol therapy for heart failure (IMPACT-HF) study: design and implications. Rev Cardiovasc Med. 2002;3(suppl 3):S48 S54.
Case 1: A 76-year-old man was diagnosed with an
CLINICIAN UPDATE -Blockers in the Post Myocardial Infarction Patient Mihai Gheorghiade, MD; Sidney Goldstein, MD Case 1: A 76-year-old man was diagnosed with an ST-segment elevation anterior wall myocardial
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationMetoprolol CR/XL in Female Patients With Heart Failure
Metoprolol CR/XL in Female Patients With Heart Failure Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) Jalal K. Ghali, MD; Ileana L.
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationHeart Failure and Cardiomyopathy Center, Division of Cardiology, North Shore University Hospital, Manhasset, NY
NEUROHORMONAL ANTAGONISTS IN THE POST-MI PATIENT New Evidence from the CAPRICORN Trial: The Role of Carvedilol in High-Risk, Post Myocardial Infarction Patients Jonathan D. Sackner-Bernstein, MD, FACC
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationThe Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationLong-Term Outcome and Tolerability of Carvedilol Therapy in Japanese Patients With Chronic Heart Failure
Long-Term Outcome and Tolerability of Carvedilol Therapy in Japanese Patients With Chronic Heart Failure Naomi Naoki Yoko Yoshie Hiroshi KAWASHIRO, MD MATSUDA, MD ENDO, MD UCHIDA, MD KASANUKI, MD, FJCC
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationBeta blockers as cardioprotective agents: Part II Focus on prevention of sudden
Beta blockers as cardioprotective agents: Part II Focus on prevention of sudden cardiac death Sidney Goldstein, MD From the Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute,
More informationCost effectiveness of beta blocker therapy for patients. with chronic severe heart failure. in Ireland. M. Barry
IMJ June 2002;95(6):174-177 Cost effectiveness of beta blocker therapy for patients with chronic severe heart failure in Ireland M. Barry Irish National Centre for Pharmacoeconomics Address for correspondence
More informationThe benefit of treatment with -blockers in heart failure is
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,
More informationJournal of the American College of Cardiology Vol. 43, No. 9, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 43, No. 9, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.12.040
More informationBeta-blockers in heart failure: evidence put into practice
Beta-blockers in heart failure: evidence put into practice John McMurray Professor of Medical Cardiology, University of Glasgow & Consultant Cardiologist,Western Infirmary, Glasgow, UK Eugene Braunwald
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationSemilogarithmic relation between rest heart rate and life expectancy
The importance of heart rate in heart failure Karl Swedberg Professor of Medicine Department t of emergency and cardiovascular medicine i Sahlgrenska Academy University of Gothenburg, Sweden karl.swedberg@gu.se
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationIncidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction
Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationDobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure
Dobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure Yuksel Cavusoglu, KU Mert, A Nadir, F Mutlu, E Gencer, T Ulus, A Birdane
More informationCardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationThe role of angiotensin II receptor blockers in the management of heart failure
European Heart Journal Supplements (2005) 7 (Supplement J), J10 J14 doi:10.1093/eurheartj/sui057 The role of angiotensin II receptor blockers in the management of heart failure John J.V. McMurray* Department
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationHeart Failure. Jay Shavadia
Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary
More informationClinical Investigation and Reports. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure
Clinical Investigation and Reports Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS)
More informationHeart Failure Management Update
Heart Failure Management Update Rafique Ahmed, MD, PhD, FACC, FCPS Consultant Cardiac Electrophysiologist Baltimore, Maryland, USA Heart Failure - Definition The situation when the heart is incapable of
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationCLINICAL PRACTICE GUIDELINE
CLINICAL PRACTICE GUIDELINE Procedure: Congestive Heart Failure Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationNew Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD
New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD Professor of Medicine, Cell Biology, Radiology and Surgery Director, The Howard Gilman Institute for Heart Valve Disease and the Schiavone
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationHeart failure update Treatment of heart failure with a normal left ventricular ejection fraction in the elderly
HEART FAILURE Heart failure update Treatment of heart failure with a normal left ventricular ejection fraction in the elderly Wilbert S. Aronow, MD Heart failure (HF) affects approximately 5 million persons
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationJournal of the American College of Cardiology Vol. 52, No. 24, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 52, No. 24, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.09.011
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationKnown Actions of Digoxin
Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationDiastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012
Diastolic Heart Failure Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012 Disclosures Have spoken for Merck, Sharpe and Dohme Sat on a physician advisory
More information1200 β-blockers in CHF Mayo Clin Proc, November 2002, Vol 77 Table 1. Summary of Major Mortality Trials Evaluating β-blockers in Patients With Heart F
Mayo Clin Proc, November 2002, Vol 77 β-blockers in CHF 1199 Review β-blockers in Chronic Heart Failure: Considerations for Selecting an Agent MARRICK L. KUKIN, MD Patients with chronic heart failure have
More informationSara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012
Sara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012 Disclosure: Dr. Weiss has no significant financial interest in any of the products or manufacturers mentioned.
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationDepartments of Medicine and Cardiology, Heart Failure/Transplantation Services, University of Texas Southwestern Medical Center, Dallas, TX
IMPROVING HEART FAILURE CARE Special Clinical Considerations of Beta-Blocker Treatment Clyde W. Yancy, MD Departments of Medicine and Cardiology, Heart Failure/Transplantation Services, University of Texas
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationNora Goldschlager, M.D. SFGH Division of Cardiology UCSF
CLASSIFICATION OF HEART FAILURE Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF DISCLOSURES: NONE CLASSIFICATION C OF HEART FAILURE NYHA I IV New paradigm Stage A: Pts at high risk of developing
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More informationRate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications.
Article ID: WMC004618 ISSN 2046-1690 Rate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications. Peer review status: No Corresponding
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationHeart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationBeta-Blocker Therapy and Severe Heart Failure: Myth or Reality?
BETA BLOCKERS AND HF CHF JULY/AUGUST 2003 197 Beta-Blocker Therapy and Severe Heart Failure: Myth or Reality? The medical management of heart failure has undergone remarkable progress in the past 10 years.
More informationDespite declining age-adjusted incidence and mortality
Sex Differences in the Prognosis of Congestive Heart Failure Results From the Cardiac Insufficiency Bisoprolol Study (CIBIS II) Tabassome Simon, MD; Murielle Mary-Krause, PhD; Christian Funck-Brentano,
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationEpidemiology of Symptomatic Heart Failure in the U.S.
William T. Abraham, MD, FACP, FACC, FAHA, FESC Professor of Medicine, Physiology, and Cell Biology Director, Division of Cardiovascular Medicine Deputy Director Davis Heart and Lung Research Institute
More informationTreating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks
Treating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks 12th Annual Leadership Summit on Health Disparities & Congressional Black Caucus Spring Health
More informationChapter (9) Calcium Antagonists
Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationThe NEW Heart Failure Guidelines
The NEW Heart Failure Guidelines Daily Practice HF scenario of the Case Presentations HF as a complex and heterogeneous syndrome Several proposed pathophysiological mechanisms involving the heart and the
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationIdentification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study
Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Dr. Antonio Magaña M.D. (on behalf I-PREFER investigators group) Stockholm, Sweden, August
More information